FDA approves saxagliptin (Onglyza) labeling to include patients with CKD PDF Print
Bloomberg: Bristol-Myers Squibb Co. and AstraZeneca PLC said Wednesday they are expanding the label of their diabetes drug Onglyza, adding information about the drug's effects in patients with kidney failure.

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.